4/A: Unicycive Director Receives RSU Equity Grant
Statement of Changes in Beneficial Ownership
Director Sara Kenkare-Mitra was granted 126,300 restricted stock units in Unicycive Therapeutics, Inc.
Summary
- Director Sara Kenkare-Mitra received two separate grants of restricted stock units (RSUs) on May 14, 2026.
- The first grant consists of 84,200 RSUs, with 11,694 vesting immediately and the remainder vesting monthly over 31 months starting June 1, 2026.
- The second grant consists of 42,100 RSUs, with 17,542 vesting immediately and the remainder vesting monthly over 7 months starting June 1, 2026.
- All RSUs are payable solely in common stock of Unicycive Therapeutics, Inc.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Equity-based compensation aligns the interests of the director with those of the shareholders.
- The vesting schedule encourages long-term retention of the director.
Negatives
- The issuance of new RSUs results in potential future dilution for existing shareholders.
Risks
- Vesting is subject to the director's continued service with the issuer.
- Market volatility could impact the future value of the equity granted.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with long-term shareholder value creation.
Comparison to Industry Standards
- The use of RSU grants for board compensation is consistent with standard practices for small-cap biotech firms.
- Vesting schedules tied to continued service are typical for director compensation packages.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual conversion of RSUs into common stock.
Next Steps
- Monthly vesting of RSU awards beginning June 1, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of RSU grant transaction |
| 05/21/2026 | Date of original filing |
| 06/01/2026 | Commencement of monthly vesting for both RSU awards |
| 06/15/2026 | Date of signature on the filing |
Keywords
Unicycive Therapeutics, UNCY, Form 4, Insider Trading, Equity Compensation, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.